Bimatoprost insert

Drug Profile

Bimatoprost insert

Alternative Names: Bimatoprost HELIOS™ insert; Bimatoprost sustained release insert - ForSight Vision5; Vision-5-product

Latest Information Update: 17 Aug 2016

Price : $50

At a glance

  • Originator ForSight VISION5
  • Class Amides; Amino alcohols; Antiglaucomas; Lipids; Morpholines; Propanolamines; Prostaglandins; Small molecules; Thiadiazoles
  • Mechanism of Action Prostaglandin F2alpha receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Glaucoma; Ocular hypertension

Most Recent Events

  • 01 Aug 2016 ForSight Vision5 completes a phase I/II extension trial for Glaucoma and Ocular hypertension in USA (NCT02537015)
  • 15 Mar 2016 Biomarkers information updated
  • 01 Jan 2016 ForSight VISION5 completes the phase I/II extension trial in Glaucoma and Ocular hypertension in USA (NCT02143843)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top